New Treatment Regime for Aspergillus Mediated Infections

Abstract

Aspergillus species such as A. fumigatus , A. flavus and A. terreus are among the leading opportunistic fungal infections in immunocompromised patients. They are the causative agent of pulmonary or invasive aspergillosis, or various allergic manifestations such as allergic bronchopulmonary aspergillosis (ABPA) [1]. The mortality rate is 60% to 85% in hematopoietic stem cell transplant patients and 22% in patients having solid organ transplant [2]. The emergence of drug resistance Aspergillus species possess a new threat to these individuals. Over the last few years, the use of azole fungicides in agriculture have been increased that lead to emergence of azole resistant Aspergillus species strains [3]. Chowdhary et al. reported the prevalence of triazole resistance environmental isolates of A. fumigatus (4.8% to 7%) over different years.